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Objective: in CF, multiresistant PA colonizes some patients. Recently, synergy in
vitro of more than two antibiotics appeared to be relevant. We report the synergy
effect of cotrimoxazole (TMP-SMX) in triple association of antibiotics and the
clinical evaluation of such treatment in patient with broad multiresistant PA.
Methods: The identiﬁcation and sensitivity testing method was based on applying
a gradient of antibiotic (E-test strip) onto an agar plate inoculated with the sputum
(Zebouh M, Pathol Biol 2005). A synergy of three antibiotics was sought in PA
multiresistant deﬁned by the impossibility to obtain a synergy by combining 2 major
antibiotics (beta-lactam, ceftazidime (CFZ), tobramycin (TOBRA), ciproﬂoxacin
(CIPRO) and meropenem (MERO). The in vitro results stated on no, additional
or synergic effect of the association. The treatment was evaluated with pulmonary
function tests (PFTs) and clinical outcome.
Results: 22 triple-antibiotic courses were administered in 12 patients. Syn-
ergy was obtained in 18 of 22 (82%): CFZ+TOBRA+TMP-SMX (n = 5),
MERO+TOBRA+TMP-SMX (n = 4), MERO+CIPRO+SMX-TMP (n = 6) and other
combination (n = 4). An additional effect was found in 18%. We reported a clinical
efﬁcacy in 92.3%, based on the decrease of cough scoring and self reported sputum
volume. Conversely, sputum bacterial density decreased in 30.7% and PFTs were
improved in only 19.2% of these patients with a severe CF disease.
Conclusion: TMP-SMX allowed recovering a synergic effect when associated to
two major antibiotics against PA. Although cough scoring decreased, objective
clinical effect remained inconstant in these however patients who had a severe
CF disease.
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Antibiotic-resistant bacterial infections are becoming a worldwide problem related
to diseases such as cystic ﬁbrosis (CF).
The purpose of this study was the evaluation of epidemiology and resistance proﬁles
of multiresistant pathogens selected over a 3-year period from 1000 CF patients
attending Florence and Verona CF Centers.
The minimum inhibitory concentrations (MICs) of most commonly used antibiotics
were evaluated by E-test on 49 multiresistant strains: 25 Pseudomonas aeruginosa
(PA) and 24 Burkholderia cepacia complex (Bcc). PA isolates were identiﬁed by
use of commercial biochemical tests. The genomovar status of Bcc isolates was
determined by recA-based PCR assays, and the IS1363 (pertaining to epidemic
clones) PCR assay was performed on isolates belonging to B. cenocepacia. Random
ampliﬁed polymorphic DNA (RAPD) ﬁngerprinting was performed on both Bcc and
PA isolates to investigate clonal relations.
Ticarcillin, ceftazidime and meropenem were the most active drugs, inhibiting 52%
and 44% of PA strains, respectively. Meropenem temocillin and ceftazidime were the
most active agent against Bcc strains inhibiting 70.8%, 66.6%, 50.1% respectively.
The majority of Bcc isolates belong to B. cenocepacia (17 out of 24 isolates) the
III-B lineage being the most represented (10 out of 17 isolates). One out of these
17 isolates gave positive results to the IS1363 PCR test. Both PA and Bcc RAPD
analysis did not show the presence of related clones.
These data show that multiresistant PA and Bcc isolates do not have epidemic
behaviour in spite of their high rate of resistance.
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The cost of anti-Pseudomonas aeruginosa (PA) antibiotic therapy in various stages
of the infection in cystic ﬁbrosis (CF) patients has not often been evaluated.
Aims: To analyze the cost of early eradication treatment versus antibiotic therapy in
patients chronically infected by PA and to study the breakdown of costs according
to type of treatment and administration route in outpatients and inpatients.
Methods: Analysis of antibiotic prescriptions (2002–2006) for 114 (61.9%) of 184
patients in which PA was isolated. The antibiotic cycles and cost of early eradication
treatment was compared to treatment of chronic infection.
Results: 61 CF patients were administered 253 cycles of early eradication treatment
(oral and inhalation antibiotics) costing a total of €384,207 (mean cost was
€1,259/patient/yr). The total cost of antibiotic treatment for patients with chronic
infection was €2,303,852 (€2,125,733 for outpatients and €115,119 for inpatients)
with a mean cost of €8,694/patient/yr. Cost breakdown for antibiotic therapy for
chronically infected outpatients was 95% and 5% for inpatients.
Discussion: 85% of the cost of antibiotic therapy is attributable to patients with
chronic PA infection whereas 15% is for those given early eradication antibiotic
treatment. The mean annual cost for a patient treated with early eradication
treatment is one-seventh that of the mean annual cost for a chronically infected
patient. Therefore, emphasis should be placed on early eradication therapy as being
more cost effective.
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Background and Methods: Two Phase 3 placebo-controlled studies were con-
ducted to evaluate the clinical efﬁcacy of a 28-day course of AZLI in patients
with CF. Data from these studies were pooled for analysis. In an effort to determine
whether Pseudomonas aeruginosa (PA) susceptibility to aztreonam is predictive of
clinical response to AZLI therapy, changes in CFQ-R respiratory symptoms score,
FEV1, and sputum PA density were analyzed by highest aztreonam MIC for PA
from each patient.
Results: Patients treated with AZLI demonstrated signiﬁcant clinical improvements
relative to placebo, regardless of whether the highest aztreonam MIC for PA at
baseline was above or below the parenteral breakpoint of 8mg/mL (see table). AZLI-
treated patients with more susceptible isolates demonstrated greater reductions in
sputum PA density; however, improvements in CFQ-R respiratory symptoms score
and FEV1 were similar between susceptibility groups. Robust clinical responses
were also observed among patients whose highest aztreonam MIC for PA increased
( 4-fold) to above the parenteral breakpoint following AZLI therapy.
Conclusion:Microbiologic resistance of PA to aztreonam does not appear to predict
clinical efﬁcacy of AZLI in patients with CF; no MIC value was identiﬁed that
correlated with a lack of response to therapy.
Highest baseline MICa N Treatment differenceb at day 28
Change in CFQ-R respiratory
symptoms score
Percent change
in FEV1
Change in log10 PA
density in sputum
MIC 8mg/mL 123 6.60 8.42 −1.22
MIC> 8mg/mL 68 7.30 7.60 −0.63
aHighest aztreonam MIC for PA at baseline.
bDeﬁned as Mean [AZLI] − Mean [Placebo]; p< 0.05 for all values.
